Information diABZI STING agonist (Compound 3) diABZI STING agonist (diABZI STING agonist-1, Compound 3) is a potent non-nucleotide STING agonist and has tremendous potential to improve treatment of cancer in humans. Targets STING In vitro In human PBMCs, compound 3 induces dose-dependent activation of STING and secretion of IFNβ with an EC50 app of 130 nM. In vivo Compound 3 activates secretion of IFNβ, IL-6, TNF, and KC/GROα (also known as CXCL1) in wild-type but not Sting −/− mice. In BALB/c mice administrated 3 mg/kg compound 3 via intravenous injection, compound 3 exhibits systemic exposure with a half-life of 1.4 h and achieves systemic concentrations greater than the half-maximal effective concentration (EC50) for mouse STING (~200 ng/ml). In mice bearing subcutaneous CT-26 tumours, treatment with compound 3 results in significant tumour growth inhibition as measured by tumour volume AUC analysis (P